Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Squamous Cell | 8 | 2024 | 4033 | 2.060 |
Why?
|
Multiple Myeloma | 29 | 2024 | 5185 | 1.570 |
Why?
|
Skin Neoplasms | 8 | 2022 | 5691 | 1.410 |
Why?
|
Cyclin D1 | 2 | 2024 | 463 | 0.850 |
Why?
|
Neoplasm Staging | 6 | 2022 | 11036 | 0.740 |
Why?
|
Chromosome Aberrations | 8 | 2022 | 1811 | 0.710 |
Why?
|
Peripheral Nerves | 1 | 2020 | 466 | 0.570 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 689 | 0.490 |
Why?
|
Plasma Cells | 8 | 2017 | 593 | 0.490 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2019 | 3591 | 0.450 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2009 | 0.430 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2021 | 604 | 0.410 |
Why?
|
Thalidomide | 5 | 2017 | 890 | 0.400 |
Why?
|
Paraproteinemias | 4 | 2016 | 246 | 0.390 |
Why?
|
Cyclin D2 | 2 | 2024 | 101 | 0.370 |
Why?
|
Prognosis | 21 | 2022 | 29052 | 0.360 |
Why?
|
Mutation, Missense | 1 | 2019 | 2566 | 0.360 |
Why?
|
Head and Neck Neoplasms | 1 | 2024 | 2736 | 0.350 |
Why?
|
Genome, Human | 2 | 2021 | 4418 | 0.320 |
Why?
|
Neoplasm Invasiveness | 3 | 2021 | 3617 | 0.310 |
Why?
|
Dexamethasone | 5 | 2020 | 1950 | 0.290 |
Why?
|
Colorectal Neoplasms | 6 | 2023 | 6773 | 0.280 |
Why?
|
Syndecan-1 | 2 | 2018 | 165 | 0.260 |
Why?
|
DNA | 1 | 2019 | 7295 | 0.260 |
Why?
|
Gene Expression Profiling | 10 | 2024 | 9440 | 0.260 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5230 | 0.260 |
Why?
|
Gene Expression Regulation, Neoplastic | 13 | 2022 | 8430 | 0.250 |
Why?
|
Loss of Heterozygosity | 2 | 2020 | 684 | 0.250 |
Why?
|
DNA Copy Number Variations | 5 | 2021 | 1937 | 0.240 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 973 | 0.240 |
Why?
|
Cyclin D | 1 | 2024 | 72 | 0.240 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2019 | 3524 | 0.230 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2019 | 2649 | 0.230 |
Why?
|
Gene Dosage | 4 | 2016 | 1252 | 0.220 |
Why?
|
Immunophenotyping | 7 | 2016 | 1880 | 0.220 |
Why?
|
DNA Methylation | 5 | 2022 | 4286 | 0.210 |
Why?
|
Algorithms | 2 | 2020 | 13869 | 0.210 |
Why?
|
Amiloride | 2 | 2022 | 121 | 0.210 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 2 | 2015 | 177 | 0.200 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2022 | 2944 | 0.200 |
Why?
|
Breathing Exercises | 1 | 2021 | 53 | 0.190 |
Why?
|
Chromosomes, Human | 2 | 2014 | 457 | 0.190 |
Why?
|
KCNQ2 Potassium Channel | 1 | 2021 | 24 | 0.190 |
Why?
|
Thrombocythemia, Essential | 1 | 2022 | 105 | 0.190 |
Why?
|
Retrospective Studies | 9 | 2022 | 77410 | 0.190 |
Why?
|
Aged, 80 and over | 13 | 2022 | 57744 | 0.190 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2022 | 134 | 0.190 |
Why?
|
Carcinoma, Pancreatic Ductal | 3 | 2018 | 1637 | 0.190 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 169 | 0.190 |
Why?
|
Athletic Performance | 1 | 2021 | 95 | 0.190 |
Why?
|
Humans | 59 | 2024 | 743811 | 0.180 |
Why?
|
Osteogenesis | 2 | 2017 | 1291 | 0.180 |
Why?
|
Chromosome Breakpoints | 1 | 2019 | 98 | 0.180 |
Why?
|
Leukemia, Plasma Cell | 1 | 2019 | 48 | 0.170 |
Why?
|
DNA Mutational Analysis | 2 | 2019 | 4183 | 0.170 |
Why?
|
Lung Neoplasms | 1 | 2024 | 13112 | 0.170 |
Why?
|
Drug Synergism | 3 | 2017 | 1794 | 0.160 |
Why?
|
Serum Amyloid P-Component | 1 | 2018 | 47 | 0.160 |
Why?
|
Hematologic Neoplasms | 2 | 2022 | 1832 | 0.160 |
Why?
|
Nucleotidyltransferases | 1 | 2020 | 220 | 0.160 |
Why?
|
Mesenchymal Stem Cells | 2 | 2019 | 1632 | 0.150 |
Why?
|
Thiadiazoles | 1 | 2017 | 55 | 0.150 |
Why?
|
Karyotyping | 1 | 2019 | 1243 | 0.150 |
Why?
|
Antigens, CD34 | 1 | 2019 | 658 | 0.150 |
Why?
|
Tumor Burden | 2 | 2020 | 1917 | 0.140 |
Why?
|
Telomere | 1 | 2023 | 910 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 1 | 2016 | 34 | 0.140 |
Why?
|
Immunoglobulins | 1 | 2020 | 881 | 0.140 |
Why?
|
Gamma Rays | 1 | 2017 | 320 | 0.140 |
Why?
|
RNA, Messenger | 5 | 2020 | 13028 | 0.140 |
Why?
|
Opportunistic Infections | 1 | 2018 | 389 | 0.130 |
Why?
|
MicroRNAs | 5 | 2020 | 3750 | 0.130 |
Why?
|
Incidental Findings | 1 | 2020 | 689 | 0.130 |
Why?
|
Lectins, C-Type | 1 | 2018 | 589 | 0.130 |
Why?
|
Protective Agents | 1 | 2016 | 156 | 0.130 |
Why?
|
Immunoglobulin Light Chains | 1 | 2016 | 277 | 0.130 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6311 | 0.130 |
Why?
|
Antibody Formation | 1 | 2020 | 1402 | 0.130 |
Why?
|
Adipogenesis | 1 | 2017 | 357 | 0.130 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14714 | 0.130 |
Why?
|
Systems Integration | 1 | 2016 | 440 | 0.120 |
Why?
|
Genomics | 6 | 2016 | 5714 | 0.120 |
Why?
|
Aged | 20 | 2021 | 163178 | 0.120 |
Why?
|
Pancreaticoduodenectomy | 1 | 2018 | 503 | 0.120 |
Why?
|
Immunoassay | 1 | 2018 | 751 | 0.120 |
Why?
|
Diuretics | 1 | 2017 | 591 | 0.120 |
Why?
|
Interphase | 1 | 2014 | 226 | 0.120 |
Why?
|
Pancreatic Neoplasms | 3 | 2018 | 5264 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 7 | 2021 | 15518 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1781 | 0.120 |
Why?
|
Plasmacytoma | 1 | 2014 | 183 | 0.120 |
Why?
|
Burkitt Lymphoma | 1 | 2015 | 326 | 0.110 |
Why?
|
Cell Line, Tumor | 10 | 2020 | 16674 | 0.110 |
Why?
|
Interleukin-8 | 1 | 2016 | 690 | 0.110 |
Why?
|
Phagocytosis | 1 | 2018 | 1539 | 0.110 |
Why?
|
Male | 24 | 2022 | 349776 | 0.110 |
Why?
|
Developmental Disabilities | 1 | 2021 | 1452 | 0.100 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2015 | 436 | 0.100 |
Why?
|
Nanotechnology | 1 | 2018 | 708 | 0.100 |
Why?
|
Drainage | 1 | 2018 | 1142 | 0.100 |
Why?
|
Open Reading Frames | 1 | 2015 | 811 | 0.100 |
Why?
|
Myelodysplastic Syndromes | 1 | 2022 | 1352 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 602 | 0.100 |
Why?
|
RNA, Untranslated | 1 | 2015 | 452 | 0.100 |
Why?
|
Cytogenetic Analysis | 3 | 2022 | 294 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2021 | 1205 | 0.100 |
Why?
|
Female | 24 | 2022 | 380020 | 0.100 |
Why?
|
Bone Marrow Cells | 1 | 2019 | 2509 | 0.100 |
Why?
|
Genetic Predisposition to Disease | 4 | 2021 | 17439 | 0.100 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2016 | 685 | 0.090 |
Why?
|
Antineoplastic Agents | 3 | 2022 | 13691 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5532 | 0.090 |
Why?
|
Pilot Projects | 1 | 2022 | 8316 | 0.090 |
Why?
|
Phenotype | 8 | 2021 | 16361 | 0.090 |
Why?
|
Amyloidosis | 1 | 2016 | 795 | 0.090 |
Why?
|
Bone Marrow | 1 | 2019 | 2951 | 0.080 |
Why?
|
Flow Cytometry | 3 | 2015 | 5973 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 3089 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2016 | 5170 | 0.080 |
Why?
|
Risk | 1 | 2021 | 9677 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4437 | 0.080 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 4803 | 0.080 |
Why?
|
Hematopoiesis | 1 | 2017 | 2073 | 0.080 |
Why?
|
Base Sequence | 1 | 2019 | 12798 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2016 | 2504 | 0.080 |
Why?
|
B-Lymphocytes | 3 | 2017 | 4665 | 0.080 |
Why?
|
Computational Biology | 2 | 2016 | 3515 | 0.080 |
Why?
|
Middle Aged | 18 | 2023 | 213241 | 0.080 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 2110 | 0.070 |
Why?
|
Chromosomes, Human, Pair 11 | 2 | 2020 | 417 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2022 | 9239 | 0.070 |
Why?
|
C-Reactive Protein | 1 | 2018 | 3778 | 0.070 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 1520 | 0.070 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2938 | 0.070 |
Why?
|
Skin | 1 | 2020 | 4372 | 0.070 |
Why?
|
Gene Frequency | 3 | 2020 | 3585 | 0.070 |
Why?
|
Ikaros Transcription Factor | 2 | 2020 | 217 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2017 | 2914 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 933 | 0.070 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2015 | 1052 | 0.070 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5524 | 0.070 |
Why?
|
Bone and Bones | 1 | 2016 | 2576 | 0.070 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15067 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2942 | 0.060 |
Why?
|
Comparative Genomic Hybridization | 2 | 2016 | 496 | 0.060 |
Why?
|
Graft vs Host Disease | 1 | 2016 | 2958 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2021 | 7880 | 0.060 |
Why?
|
CpG Islands | 2 | 2021 | 1170 | 0.060 |
Why?
|
Risk Factors | 6 | 2022 | 72252 | 0.060 |
Why?
|
Translocation, Genetic | 2 | 2022 | 1420 | 0.060 |
Why?
|
Cell Differentiation | 2 | 2017 | 11478 | 0.060 |
Why?
|
Melphalan | 2 | 2016 | 431 | 0.060 |
Why?
|
Propidium | 1 | 2022 | 41 | 0.060 |
Why?
|
Annexin A5 | 1 | 2022 | 103 | 0.050 |
Why?
|
Alternative Splicing | 2 | 2019 | 1117 | 0.050 |
Why?
|
Cell Survival | 3 | 2017 | 5881 | 0.050 |
Why?
|
Osteoclasts | 2 | 2016 | 729 | 0.050 |
Why?
|
Clone Cells | 2 | 2016 | 1692 | 0.050 |
Why?
|
Microarray Analysis | 2 | 2016 | 765 | 0.050 |
Why?
|
Cytogenetics | 1 | 2022 | 203 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2020 | 10477 | 0.050 |
Why?
|
Coculture Techniques | 2 | 2016 | 1342 | 0.050 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 3645 | 0.050 |
Why?
|
Risk Assessment | 1 | 2022 | 23327 | 0.050 |
Why?
|
Prospective Studies | 2 | 2024 | 53250 | 0.050 |
Why?
|
Respiratory Muscles | 1 | 2021 | 139 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2016 | 4251 | 0.050 |
Why?
|
Treatment Outcome | 6 | 2018 | 63042 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2016 | 3917 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2021 | 2712 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11524 | 0.050 |
Why?
|
Respiratory Therapy | 1 | 2021 | 132 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 6539 | 0.050 |
Why?
|
Disease Progression | 5 | 2016 | 13273 | 0.050 |
Why?
|
Apoptosis | 4 | 2017 | 9718 | 0.050 |
Why?
|
Stromal Cells | 2 | 2016 | 1356 | 0.040 |
Why?
|
Chromosomal Instability | 1 | 2021 | 183 | 0.040 |
Why?
|
Gene Duplication | 1 | 2021 | 328 | 0.040 |
Why?
|
Cell Separation | 2 | 2016 | 1750 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 380 | 0.040 |
Why?
|
Genes, p53 | 1 | 2022 | 755 | 0.040 |
Why?
|
Caspases | 1 | 2022 | 928 | 0.040 |
Why?
|
Polyadenylation | 1 | 2020 | 116 | 0.040 |
Why?
|
Interferon Regulatory Factors | 1 | 2020 | 270 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2017 | 3547 | 0.040 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2703 | 0.040 |
Why?
|
Unfolded Protein Response | 1 | 2020 | 233 | 0.040 |
Why?
|
Survival Rate | 3 | 2018 | 12786 | 0.040 |
Why?
|
Dystonia | 1 | 2021 | 363 | 0.040 |
Why?
|
Mutation | 5 | 2021 | 29777 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2021 | 684 | 0.040 |
Why?
|
Receptors, Purinergic P2Y | 1 | 2016 | 25 | 0.040 |
Why?
|
Signal Transduction | 5 | 2020 | 23398 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2022 | 1729 | 0.040 |
Why?
|
Gene Knockout Techniques | 1 | 2020 | 807 | 0.040 |
Why?
|
Cohort Studies | 1 | 2019 | 40545 | 0.040 |
Why?
|
Aspergillosis | 1 | 2018 | 235 | 0.040 |
Why?
|
Cell Cycle | 2 | 2016 | 2963 | 0.040 |
Why?
|
LDL-Receptor Related Proteins | 1 | 2016 | 115 | 0.040 |
Why?
|
Up-Regulation | 2 | 2016 | 4221 | 0.040 |
Why?
|
Adult | 10 | 2021 | 213889 | 0.030 |
Why?
|
Cell Dedifferentiation | 1 | 2017 | 135 | 0.030 |
Why?
|
Glycosyltransferases | 1 | 2016 | 113 | 0.030 |
Why?
|
Cerebral Palsy | 1 | 2021 | 459 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 1097 | 0.030 |
Why?
|
Candidiasis | 1 | 2018 | 366 | 0.030 |
Why?
|
Cyclin D3 | 1 | 2015 | 55 | 0.030 |
Why?
|
Motor Neurons | 1 | 2021 | 841 | 0.030 |
Why?
|
Mice | 6 | 2019 | 81154 | 0.030 |
Why?
|
E-Box Elements | 1 | 2014 | 21 | 0.030 |
Why?
|
Exons | 1 | 2021 | 2438 | 0.030 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2015 | 299 | 0.030 |
Why?
|
Genes, Neoplasm | 1 | 2016 | 376 | 0.030 |
Why?
|
Thiophenes | 1 | 2019 | 589 | 0.030 |
Why?
|
Synaptic Transmission | 1 | 2021 | 1176 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2022 | 1986 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1335 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3268 | 0.030 |
Why?
|
Antifungal Agents | 1 | 2018 | 729 | 0.030 |
Why?
|
Tumor Stem Cell Assay | 1 | 2013 | 118 | 0.030 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2014 | 98 | 0.030 |
Why?
|
Promoter Regions, Genetic | 2 | 2015 | 5867 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2015 | 513 | 0.030 |
Why?
|
Morpholines | 1 | 2016 | 571 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12243 | 0.030 |
Why?
|
Aminopyridines | 1 | 2016 | 543 | 0.030 |
Why?
|
Animals | 7 | 2019 | 168660 | 0.030 |
Why?
|
Standard of Care | 1 | 2016 | 564 | 0.030 |
Why?
|
Bone Resorption | 1 | 2016 | 722 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 1434 | 0.030 |
Why?
|
United States | 1 | 2020 | 69859 | 0.030 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 623 | 0.030 |
Why?
|
Principal Component Analysis | 1 | 2014 | 935 | 0.020 |
Why?
|
Quinolines | 1 | 2016 | 732 | 0.020 |
Why?
|
Integrins | 1 | 2016 | 846 | 0.020 |
Why?
|
Prednisone | 1 | 2016 | 1574 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1030 | 0.020 |
Why?
|
Demography | 1 | 2015 | 1653 | 0.020 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2015 | 571 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 2012 | 1374 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 2085 | 0.020 |
Why?
|
Imidazoles | 1 | 2016 | 1206 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 2015 | 1537 | 0.020 |
Why?
|
Family | 1 | 2021 | 3144 | 0.020 |
Why?
|
Sulfonamides | 1 | 2019 | 1938 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2016 | 1782 | 0.020 |
Why?
|
Boronic Acids | 1 | 2014 | 965 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2016 | 1602 | 0.020 |
Why?
|
Genetic Markers | 1 | 2016 | 2634 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4848 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2014 | 850 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3874 | 0.020 |
Why?
|
Preoperative Care | 1 | 2018 | 2251 | 0.020 |
Why?
|
Mice, SCID | 1 | 2014 | 2718 | 0.020 |
Why?
|
T-Lymphocytes | 2 | 2016 | 10179 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 3000 | 0.020 |
Why?
|
Seizures | 1 | 2021 | 2850 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4552 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2013 | 2123 | 0.020 |
Why?
|
Pyrazines | 1 | 2014 | 1230 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2018 | 4326 | 0.020 |
Why?
|
Cell Movement | 1 | 2020 | 5216 | 0.020 |
Why?
|
RNA Interference | 1 | 2016 | 2890 | 0.020 |
Why?
|
Remission Induction | 1 | 2013 | 2384 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2234 | 0.020 |
Why?
|
Pyrimidines | 1 | 2019 | 2945 | 0.020 |
Why?
|
Genome | 1 | 2015 | 1806 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10251 | 0.020 |
Why?
|
Genome-Wide Association Study | 2 | 2016 | 12259 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2015 | 2131 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 6170 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2016 | 18027 | 0.020 |
Why?
|
Child | 3 | 2021 | 77637 | 0.020 |
Why?
|
Young Adult | 3 | 2018 | 56392 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2014 | 1376 | 0.020 |
Why?
|
Models, Genetic | 1 | 2016 | 3492 | 0.020 |
Why?
|
Phosphorylation | 1 | 2016 | 8436 | 0.020 |
Why?
|
Epilepsy | 1 | 2021 | 3284 | 0.020 |
Why?
|
Recurrence | 1 | 2016 | 8337 | 0.020 |
Why?
|
Child, Preschool | 2 | 2018 | 40964 | 0.020 |
Why?
|
Incidence | 1 | 2023 | 20948 | 0.020 |
Why?
|
Adolescent | 3 | 2018 | 85729 | 0.020 |
Why?
|
Trans-Activators | 1 | 2014 | 2927 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6487 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2014 | 2916 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2012 | 4737 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7793 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4026 | 0.010 |
Why?
|
Lung | 1 | 2021 | 9858 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 12944 | 0.010 |
Why?
|
Circadian Rhythm | 1 | 2013 | 2620 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2017 | 19232 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2014 | 4463 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12354 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8637 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2013 | 39001 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2015 | 13980 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 25609 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 21733 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2013 | 5445 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 19894 | 0.010 |
Why?
|
Time Factors | 1 | 2016 | 40038 | 0.010 |
Why?
|
Infant | 1 | 2016 | 35122 | 0.010 |
Why?
|